The stock price of Adma Biologics Inc (NASDAQ: ADMA) has surged by 0.15 when compared to previous closing price of 20.43, but the company has seen a 2.87% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-28 that At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter’s robust Asceniv-driven momentum.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
The price-to-earnings ratio for Adma Biologics Inc (NASDAQ: ADMA) is above average at 24.24x, Company’s 36-month beta value is 0.47.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADMA is 230.40M, and currently, short sellers hold a 5.79% ratio of that floaft. The average trading volume of ADMA on June 04, 2025 was 3.65M shares.
ADMA’s Market Performance
The stock of Adma Biologics Inc (ADMA) has seen a 2.87% increase in the past week, with a -13.01% drop in the past month, and a 20.28% gain in the past quarter. The volatility ratio for the week is 1.27%, and the volatility levels for the past 30 days are at 3.33% for ADMA. The simple moving average for the past 20 days is 0.34% for ADMA’s stock, with a 9.54% simple moving average for the past 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -1.14% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.30% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Guiheen Lawrence P., who sale 7,779 shares at the price of $20.32 back on May 21 ’25. After this action, Guiheen Lawrence P. now owns 114,830 shares of Adma Biologics Inc, valued at $158,069 using the latest closing price.
Guiheen Lawrence P., the Director of Adma Biologics Inc, sale 1,221 shares at $20.12 during a trade that took place back on May 22 ’25, which means that Guiheen Lawrence P. is holding 114,830 shares at $24,567 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.53 for the gross margin
The net margin for Adma Biologics Inc stands at 0.45. The total capital return value is set at 0.33. Equity return is now at value 78.45, with 48.01 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 1.23. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 18.57.
Currently, EBITDA for the company is 147.69 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 10.66. The receivables turnover for the company is 4.62for trailing twelve months and the total asset turnover is 0.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.
Conclusion
In a nutshell, Adma Biologics Inc (ADMA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
